FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1999-2000 December 26, 1996 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: In patients infected with human immunodeficiency virus type 1 (HIV-1), immunosuppression limits the choice of drugs that may be used to treat psoriatic erythroderma. We describe a patient who had a dramatic therapeutic response to carbamazepine. This may be a new therapeutic agent for psoriasis.

The patient was a 29-year-old HIV-1–positive man with a history of plaque psoriasis, disseminated varicella–zoster virus infection, Pneumocystis carinii pneumonia, disseminated Mycobacterium avium complex infection, and a CD4+ T-cell count in peripheral blood below 10 cells per cubic millimeter. The patient's skin disease had become progressively more difficult to control. In July . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.